ivermectin · Galderma Labs Lp · NDA 206255
Soolantra
Earliest generic entry, as listed
13 Mar 2034
Blocked by patent: US 10206939, US 9089587, US 9233117, US 9233118, US 9782425. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 5 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10206939 | use U-1631 | 13 Mar 2034 |
| US 9089587 | use U-1631 | 13 Mar 2034 |
| US 9233117 | use U-1631 | 13 Mar 2034 |
| US 9233118 | use U-1631 | 13 Mar 2034 |
| US 9782425 | use U-1631 | 13 Mar 2034 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206255 · 001 · RLD | cream, topical | 1% | 13 Mar 2034 |